Traders bought shares of AbbVie Inc (NYSE:ABBV) on weakness during trading hours on Wednesday. $123.14 million flowed into the stock on the tick-up and $79.52 million flowed out of the stock on the tick-down, for a money net flow of $43.62 million into the stock. Of all stocks tracked, AbbVie had the 26th highest net in-flow for the day. AbbVie traded down ($0.55) for the day and closed at $99.69

Several equities analysts have recently weighed in on ABBV shares. Societe Generale raised their price target on AbbVie in a report on Tuesday, November 21st. Jefferies Group restated a “buy” rating and set a $107.00 price target (up from $94.00) on shares of AbbVie in a report on Friday, September 15th. Piper Jaffray Companies restated a “buy” rating and set a $100.00 price target on shares of AbbVie in a report on Friday, September 15th. Argus raised their price target on AbbVie from $90.00 to $110.00 and gave the company a “buy” rating in a report on Friday, September 29th. Finally, Zacks Investment Research upgraded AbbVie from a “hold” rating to a “buy” rating and set a $102.00 price target for the company in a report on Tuesday, October 17th. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $100.94.

The company has a debt-to-equity ratio of 5.08, a quick ratio of 1.32 and a current ratio of 1.45. The firm has a market cap of $159,580.00, a PE ratio of 24.26, a P/E/G ratio of 1.20 and a beta of 1.53.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 27th. The company reported $1.41 EPS for the quarter, beating the consensus estimate of $1.39 by $0.02. AbbVie had a return on equity of 153.80% and a net margin of 24.38%. The company had revenue of $7 billion for the quarter, compared to analysts’ expectations of $7 billion. During the same period last year, the firm posted $1.21 earnings per share. AbbVie’s revenue was up 8.8% compared to the same quarter last year. sell-side analysts forecast that AbbVie Inc will post 5.55 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, February 15th. Investors of record on Friday, January 12th will be given a dividend of $0.71 per share. The ex-dividend date of this dividend is Thursday, January 11th. This is a boost from AbbVie’s previous quarterly dividend of $0.64. This represents a $2.84 annualized dividend and a dividend yield of 2.84%. AbbVie’s dividend payout ratio (DPR) is 62.14%.

In related news, insider Henry O. Gosebruch sold 18,300 shares of the stock in a transaction on Monday, October 30th. The stock was sold at an average price of $90.55, for a total transaction of $1,657,065.00. Following the sale, the insider now directly owns 81,287 shares of the company’s stock, valued at $7,360,537.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Chairman Richard A. Gonzalez sold 218,193 shares of the stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $94.01, for a total value of $20,512,323.93. Following the sale, the chairman now directly owns 492,030 shares in the company, valued at $46,255,740.30. The disclosure for this sale can be found here. Insiders have sold 494,676 shares of company stock worth $47,237,938 over the last ninety days. 0.23% of the stock is currently owned by insiders.

Large investors have recently made changes to their positions in the business. Savant Capital LLC boosted its position in AbbVie by 1.3% in the second quarter. Savant Capital LLC now owns 61,132 shares of the company’s stock worth $4,433,000 after purchasing an additional 793 shares during the last quarter. Princeton Capital Management Inc. purchased a new position in AbbVie in the second quarter worth about $1,394,000. Palisade Asset Management LLC boosted its position in AbbVie by 17.9% in the second quarter. Palisade Asset Management LLC now owns 68,311 shares of the company’s stock worth $4,953,000 after purchasing an additional 10,381 shares during the last quarter. Beaton Management Co. Inc. purchased a new position in AbbVie in the second quarter worth about $528,000. Finally, Greatmark Investment Partners Inc. boosted its position in AbbVie by 3.7% in the second quarter. Greatmark Investment Partners Inc. now owns 35,178 shares of the company’s stock worth $2,551,000 after purchasing an additional 1,242 shares during the last quarter. 69.18% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Traders Buy AbbVie (ABBV) on Weakness” was posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://www.watchlistnews.com/traders-buy-abbvie-abbv-on-weakness/1804463.html.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with Analyst Ratings Network's FREE daily email newsletter.